Merck & Company, Inc. (MRK)

Merck & Company, Inc.'s Q·Score is 6.3/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. 71% of 28 covering analysts have a positive rating. Key area to monitor: weak profitability metrics drag quality score. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for MRK is $147.77, based on ratings from 26 Wall Street analysts. This is 3.1% below the current price of $152.55. Price targets are forward-looking estimates and not guarantees of future performance.

Merck & Company, Inc. (MRK) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 16.0×.

Merck & Company, Inc.'s next earnings report is expected on approximately October 29, 2026.

Merck & Company, Inc. has a net profit margin of 4.8%, which is positive but relatively thin. Its gross margin stands at 75.9%, indicating a high-margin business model.

Merck & Company, Inc. currently offers a dividend yield of 2.23%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.

Merck & Company, Inc. is reporting modest revenue growth of 5.1%.

Merck & Company, Inc. has a debt-to-equity ratio of 1.28×, reflecting a moderately high debt load — watch cash flow coverage. Its current ratio is 1.32×, suggesting it should be monitored for near-term liquidity.